Please assess the completion status of the following clinical trial:

Trial Title: Characteristics of Glargine in Type 2 Diabetics

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 12 adults (males or females) with type 2 diabetes for at least six (6) months. May be using oral agents (SUs, metformin, acarbose or glitinides) with or without insulin.~* HgbA1c 7 -12%~* Age 18-70 years~* BMI 27-40 kg/m²~Exclusion Criteria:~* Any past or present clinically relevant abnormality, medical condition, or circumstance making the subject unsuitable for participation in the study~* Evidence of hepatic, renal or cardiac failure~* Abnormal results following screening tests~* Pregnant or lactating females or females of childbearing potential who are unwilling to abstain from sexual intercourse or use reliable, medically accepted methods of contraception~* Currently using TZDs~* History of alcoholism or drug abuse within 12 months of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo then Insulin Glargine (Type: EXPERIMENTAL): Placebo: administer single dose of Placebo subcutaneously (SC) with blood glucose monitoring over 24 hours.~Then Insulin Glargine SQ 8 weeks later, in increasing doses (0.5, 1.0, 1.5, 2.0 u/kg body wt.) with blood glucose monitoring monitoring over a 24 hour period. Each dose is separated by 8 weeks (5 separate study visits)

Based on this trial design, predict the completion outcome and termination type (if applicable).